



ophthalmology  
futures forums

Virtual2021

**RETINA FORUM**

*VIRTUAL*

Weds. 08 September



**Euro Retina Programme**  
*Virtual 2021*



# Imagine Your Happiness

Vision, a window to the world.  
With vision, we connect with others.  
With vision, we feel happiness.

That is why we at Santen believe  
seeing is integral to life.  
As a company focused on vision,  
we explore and grow the unlimited potential  
of our ability to see.  
Because we know we can one day  
achieve a world free of vision problems.  
Because we know we can one day  
create a future full of smiles  
where everyone's vision is nurtured.  
Until then, we will not stop challenging ourselves.

**Santen**

Imagine Your Happiness



# CONTENTS:

## RETINA PROGRAMME

<b>Welcome</b>	3
<b>Timings</b>	4
<b>Speakers</b>	
Presenting companies   Pannelists   Chairs	6
<b>Our sponsors</b>	7
Platinum	9
Gold	10
Silver	11
Bronze	12
New innovator	13
<b>European Forum 2021</b>	14
<b>Programme committee</b>	15



# WELCOME: RETINA VIRTUAL FORUM

Dear colleagues,

Welcome to the Ophthalmology Futures Retina Forum 2021. The virtual format for this year's forum has presented us with challenges and opportunities. While missing the chance to network with participants in person, we are able to reach a much larger audience and include speakers who would otherwise not have been able to attend.

The unique nature of innovation relating to diseases of the posterior segment led us to recognize the need for a standalone forum to increase our focus in this rapidly evolving space a few years ago and we have been delighted by the success of this format. As in prior Retina forums, we will have presentations from companies at various stages of the innovation process and panels on topics deemed to be of interest to all stakeholders. Ophthalmology Futures is dedicated to creating a novel program for each meeting.

This Forum will highlight developments in the treatment of Dry AMD, home monitoring, surgical robotics and personalized approaches for posterior segment diseases.

We will look to the future of drug delivery as well as gene therapy for rare and common retinal diseases. An interview with Dr. Anthony Adamis will undoubtedly be one of the highlights of the day.

Ophthalmology Futures Forums thanks our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to have this meeting without a registration fee for all attendees!

Thank you for joining us!

The Ophthalmology Futures Team



Vision Futures Limited, London, UK.  
Registered in England No: 8125858.



# TIMINGS:

## RETINA VIRTUAL FORUM

TIMMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

13:50 - 14:00

### WELCOME

- Keith Barton
- Kuldev Singh

14:00 - 14:30

### PANEL 1: PERSONALIZED APPROACH TO BACK OF THE EYE THERAPEUTICS

Chair

- Adnan Tufail

Panellists

- Jill Hopkins
- Daniela Ferrara
- Jay Duker
- Jason Ehrlich
- Almira Chabi
- Einar Stefánsson

14:30 - 15:00

### PANEL 2: GENE THERAPY & GENE EDITING FOR RARE & COMMON RETINAL DISEASES

Co-chairs

- Bart Leroy
- Dominik Fischer

Panellists

- Olivier Danos
- Magali Taiel
- Gil Carrasquinho
- Thomas Ciulla

15:00 - 16:00

### COMPANY PRESENTATIONS I

- REGENXBIO | Stephen Pakola
- GenSight Biologics S.A. | Magali Taiel
- Eyeevensys | Francine Behar-Cohen
- Iveric Bio | Pravin Dugel
- Santen Cell Therapy | Gil Carrasquinho
- ForwardVue Pharma | Alan Franklin

16:00 - 16:30

### PANEL 3: DRY AMD THERAPY: WILL WE GET THERE & WHO WILL PAY?

Co-chairs

- Sophie Bakri
- Sobha Sivaprasad

Panellists

- Keith Lane
- Chris Brittain
- Melissa Liew
- Pravin Dugel
- Kourous Rezaei

16:30 - 17:10

### PANEL 4: INVESTMENT OVERVIEW

Introduction

- Michael Giaquinto

Chair

- Michael Giaquinto

Panellists

- Geert-Jan Mulder
- Begoña Carreño
- Alex Pasteur
- Eugene de Juan

17:10 - 18:10

### COMPANY PRESENTATIONS 2

- Ocuphire Pharma | Mina Sooch
- OcuTerra Therapeutics | Kerrie Brady
- Pleryon Therapeutics | Yu Yu
- MONA.health | Olivier Menage
- Notal Vision Ltd | Kester Nahen
- Visotec GmbH | Helge Sudkamp

18:10 - 18:40

### PANEL 5: HOME MONITORING & REAL WORLD DATA TO ACCELERATE POSTERIOR SEGMENT INNOVATION

Co-chairs

- Francesco Bandello
- Usha Chakravarthy

Panellists

- Art Ciociola
- Kester Nahen
- Helge Sudkamp
- Angelo Rago
- Sally Tucker
- Einar Stefánsson
- David Crabb

18:40 - 19:10

### PANEL 6: SUSTAINED DRUG DELIVERY FOR AMD: MAINSTREAM CARE OR AN EXPENSIVE SIDE SHOW?

Co-chairs

- Ursula Schmidt-Erfurth
- Ramin Tadayoni

Panellists

- Jaya Chidambaram
- Cynthia Grosskreutz
- Ram Palanki
- Fred Guerard

19:10 - 19:30

### ONE ON ONE

- Kuldev Singh
- Anthony Adamis

19:30 - 20:30

### COMPANY PRESENTATIONS 3

- Clearside Biomedical | Thomas Ciulla
- EyePoint Pharmaceuticals | Nancy Lurker
- Re-Vana Therapeutics | Michael O'Rourke
- Samsara Vision | Mike Besserman
- Preceyes | Gerrit Naus

20:30 - 21:00

### PANEL 7: SURGERY AND ROBOTICS: THE NEXT FRONTIER?

Co-chairs

- Stan Rizzo
- Borja Corcostegui

Panellists

- Paul Hallen
- Gregg Draudt
- Steve Charles
- Paulo Stanga
- Eugene de Juan

21:00 - 21:10

### SUMMARY

- Adnan Tufail


21:10 - 21:15

### SUMMARY & CONCLUDING COMMENTS

- Keith Barton
- Kuldev Singh



## VISUAL FREEDOM IN ONE EXCEPTIONAL LENS



**Visian Toric ICL** provides outstanding refractive outcomes in patients with myopia and astigmatism<sup>1</sup>.

### The Visian Toric ICL clinical trial reported<sup>1</sup>:

- **98.4%** of patients would have the Visian Toric ICL procedure again
- Predictable outcomes realized across a broad range of treatment options
- **93.8%** of eyes maintained or gained 1 or more lines of BSCVA
- Rapid and stable achievement of outstanding MRSE and MRCyl
- In eyes with pre-op BSCVA 20/20 or better **100%** of eyes obtained **20/40** or better UCVA
- Over **94%** of eyes maintained rotational stability of **≤5°** at all post-op time points

1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014

# SPEAKERS: PRESENTING COMPANIES PANNELISTS & CHAIRS

## CHAIRS & PANELLISTS

### A

- **Adnan Tufail**  
Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust
- **Alex Pasteur**  
Partner, F-Prime Capital
- **Almira Chabi**  
VP, Glaucoma & Neuroprotection; AI Lead, Santen Pharmaceutical Co. Ltd.
- **Angelo Rago**  
Global Head of Ophthalmic Diagnostics, Carl Zeiss Meditec, Inc.
- **Anthony Adamis**  
Formerly Vice President & Global Head of Ophthalmology, Genentech
- **Arthur Ciociola**  
Vice President Global Head Regulatory Affairs Ophthalmology, Novartis Pharma AG

### B

- **Bart Leroy**  
Professor of Ophthalmology, Ghent University Hospital
- **Begoña Carreño**  
Global Head BDL Ophthalmology, Novartis Pharma AG

### C

- **Chris Brittain**  
Global Head of Ophthalmology Product Development, Genentech
- **Cynthia Grosskreutz**  
VP & Global Head of Ophthalmology, Novartis Institutes for Biomedical Research

### D

- **Daniela Ferrara**  
Senior Medical Director, Roche-Genentech
- **David Crabb**  
Professor of Visual Science, City University of London
- **Dominik Fischer**  
Professor of Ophthalmology, University of Tuebingen

### E

- **Einar Stefánsson**  
Professor, University of Iceland
- **Eugene De Juan**  
Managing Partner, ForSight Labs

### F

- **Francesco Bandello**  
Professor, University Vita-Salute
- **Fred Guerard**  
CEO, Graybug Vision

### G

- **Geert-Jan Mulder**  
Managing Partner, Forbion Capital Partners
- **Gil Carrasquinho**  
Head of Cell Therapy, Santen Pharmaceutical Co., Ltd
- **Gregg Draudt**  
Director of Design, Cambridge Consultants

### H

- **Helge Sudkamp**  
CEO, Visotec GmbH

### J

- **Jason Ehrlich**  
CMO/CFO, Kodiak Sciences, Inc.
- **Jay Duker**  
Chief Strategic Scientific Officer, EyePoint Pharmaceuticals
- **Jaya Chidambaram**  
Medical Director, Roche-Genentech
- **Jill Hopkins**  
Global Head Ophthalmology Development, Novartis Pharma AG

### K

- **Keith Barton**  
Consultant, Moorfields Eye Hospital NHS Foundation Trust. Professor of Ophthalmology, UCL
- **Keith Lane**  
Vice President, Ora, Inc.
- **Kester Nahen**  
CEO, Notal Vision Ltd.
- **Kourous Rezaei**  
Associate Professor, Illinois Retina Associates/Rush University Medical Center
- **Kuldev Singh**  
Professor of Ophthalmology, Stanford University School of Medicine

### M

- **Magali Taiel**  
CMO, GenSight Biologics S.A.
- **Melissa Liew**  
VP & Global Head of Translational Medicine-Ophthalmology, Novartis Institutes for Biomedical Research

### O

- **Olivier Danos**  
Senior Vice President, Chief Scientific Officer, REGENXBIO

### P

- **Paul Hallen**  
VP, Global Head Retina, Alcon
- **Paulo Stanga**  
Professor of Ophthalmology, London Vision Clinic - Retina
- **Pravin Dugel**  
President, Iveric Bio

### R

- **Ram Palanki**  
Senior Vice President, REGENXBIO
- **Ramin Tadayoni**  
Head of Ophthalmology Department, Hôpitaux De Paris

### S

- **Sally Tucker**  
Executive Director, Ora, Inc.
- **Sobha Sivaprasad**  
Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
- **Sophie Bakri**  
Professor, Mayo Clinic
- **Stano Rizzo**  
Professor of Ophthalmology, University of Florence
- **Steve Charles**  
CEO & Founder, Charles Retina Institute

### T

- **Thomas Ciulla**  
CMO, Clearside Biomedical, Inc.

### U

- **Ursula Schmidt-Erfurth**  
Professor & Chair, Medical University of Vienna
- **Usha Chakravarthy**  
Professor, The Queen's Univeristy of Belfast

## PRESENTING COMPANIES

### A

- **Alan Franklin**  
Founder, ForwardVue Pharma

### F

- **Francine Behar-Cohen**  
Scientific Founder, Eyevensys

### G

- **Gerrit Naus**  
CEO, Preceyes B.V.
- **Gil Carrasquinho**  
Head of Cell Therapy, Santen Pharmaceutical Co., Ltd

### H

- **Helge Sudkamp**  
CEO, Visotec GmbH

### K

- **Kerrie Brady**  
CEO, OcuTerra Therapeutics
- **Kester Nahen**  
CEO, Notal Vision Ltd

### M

- **Magali Taiel**  
CMO, GenSight Biologics S.A.
- **Michael O'Rourke**  
CEO, Re-Vana Therapeutics
- **Mike Besserman**  
VP, Worldwide Marketing, Samsara Vision
- **Mina Sooch**  
CEO, Ocuphire Pharma

### N

- **Nancy Lurker**  
President & CEO, EyePoint Pharmaceuticals

### O

- **Olivier Menage**  
CEO, MONA.health

### P

- **Pravin Dugel**  
President, IVERIC bio

### T

- **Thomas Ciulla**  
CMO, Clearside Biomedical, Inc.

### S

- **Stephen Pakola**  
Senior Vice President and CMO, REGENXBIO

### Y

- **Yu Yu**  
CEO, Pleryon Therapeutics

ALL OF THE SPEAKERS FOR  
OUR EURO RETINA FORUM  
CAN BE FOUND ON OUR  
WEBSITE:  
[OPHTHALMOLOGY-  
FUTURES.COM/FORUMS](https://ophthalmology-futures.com/forums)





# SPONSORS: EURO FORUMS 2021

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.


## PLATINUM



## GOLD



## SILVER



REGENXBIO®



NOVARTIS

## BRONZE



IVERIC  
BIO



LENSAR  
CATARACT LASER WITH AUGMENTED REALITY



SIGHT  
SCIENCES

Apellis



## NEW INNOVATORS







# Stellest™ lenses:

Essilor's best solution  
to slow down myopia  
progression in  
children.

REGISTER NOW TO LEARN ABOUT THE  
FUTURE OF MYOPIA MANAGEMENT



# PLATINUM

## Alcon

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 70 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

For more information, please visit [www.alcon.com](http://www.alcon.com)

## Santen

As a global specialized company dedicated exclusively to ophthalmology, Santen brings 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide, Santen continues to grow its global presence across Asia, Europe, and North America, providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and infection to patients around the world.

For more information, please visit [www.santen.com](http://www.santen.com)





# GOLD



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL", which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: [www.discovericl.com](http://www.discovericl.com). Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

For more information, please visit the Company's website at [www.staar.com](http://www.staar.com)

## Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



### Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures Retina Forum**

[www.zeiss.com](http://www.zeiss.com)



# SILVER



Essilor International is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, and Bolon™. It also develops and markets equipment, instruments and services for eyecare professionals.

At Essilor we believe that people deserve the right vision solutions to unleash the full potential of their life, every day, all life long. That belief is anchored in the Group's mission. Essilor International is a subsidiary of EssilorLuxottica.

Please visit: [www.essilor.com](http://www.essilor.com)



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

Please visit [www.regenxbio.com](http://www.regenxbio.com)



## Seeing beyond

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. With a special focus on ophthalmology and ophthalmic surgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

For more information, please visit [www.zeiss.com/meditec/int/about-us.html](http://www.zeiss.com/meditec/int/about-us.html)



Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.

Please visit: [www.novartis.com](http://www.novartis.com)

# BRONZE



GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.

Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

Our second lead product candidate, GS030, combines gene therapy with optogenetics and is currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).

For more information, please visit [www.gensight-biologics.com](http://www.gensight-biologics.com)



Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

For more information on the Company, please visit [www.ivericbio.com](http://www.ivericbio.com)



CATARACT LASER WITH AUGMENTED REALITY

LENSAR®, Inc., the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline® IV. This includes enhancements unique to LENSAR that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions.

Enhancements include IntelliAxis Refractive Capsulorhexis®, which incorporates lenticular markings to guide precise and confident toric IOL alignment, and wireless transfer of preoperative data from multiple devices, for seamless treatment planning. Iris registration further contributes to accuracy by automatically accounting for cyclotorsion. The LENSAR Laser is revolutionizing the surgeon's ability to deliver great outcomes for astigmatic patients.

Please visit [www.lensar.com](http://www.lensar.com)



Ora is the world's leading full-service ophthalmic research organization with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn 48 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's unique models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts to maximize the value of new product initiatives.

For more information, please visit [www.oraclinical.com](http://www.oraclinical.com)



AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs and help patients achieve their best personal vision. The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that delivers true extended depth of focus and enhanced adaptability through its distinctive, wavefront-filtering, small aperture design. The IC-8 IOL received CE mark in 2015 and is available in select markets across Europe and Asia.

Visit [www.AcuFocus.com](http://www.AcuFocus.com) for more information.



Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.

At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.

Please visit: [www.apellis.eu](http://www.apellis.eu)



EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States. EyePoint's product candidate pipeline also includes YUTIQ® 50, a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye, and separately, two commercial products, YUTIQ and DEXYCU.

Please visit: [www.eyepointpharma.com](http://www.eyepointpharma.com)



Sight Sciences is a growth-stage medical device company dedicated to the development of intelligently designed and engineered products that address the underlying physiology of ophthalmic diseases. The company's portfolio consists of the OMNI® Surgical System which is a novel, implant-free device that can be used in combination with cataract surgery or as a standalone procedure, as well as the non-surgical TearCare® System which is a device that applies heat to the eyelids to remove blockage, the hallmark of MGD.

Please visit: [www.sightsciences.com](http://www.sightsciences.com)

# NEW INNOVATORS



LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.

For more information about the financing please contact Ramgopal Rao, CEO at [rrao@lensgen.com](mailto:rrao@lensgen.com) and visit [www.lensgen.com](http://www.lensgen.com)



Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug's lead product candidate, GB-102, a microparticle depot formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate, targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California.

For more information, please visit [www.graybug.vision](http://www.graybug.vision) or contact us at [info@graybug.vision](mailto:info@graybug.vision).



iSTAR Medical pioneers minimally invasive, ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma. MINInject is a supraciliary MIGS device made from STAR® material, which is soft and flexible, medical-grade silicone with a micro-porous, multi-channel geometry enabling bio-integration of surrounding tissues. Clinical trials show that IOP is reduced by >40% to a mean of 13.8mmHg at two years post-surgery.

The US Food and Drug Administration (FDA) has approved the start of a pivotal trial for MINInject.

Please visit: [www.istarmed.com](http://www.istarmed.com)



A new name in the ophthalmic industry, Medevisе Consulting brings together an experienced team to provide regulatory, clinical, market assessment and medical communication services for companies looking to succeed in Europe.

With unparalleled insight, resources and a network built up over decades of experience, we work with clients to build long-term relationships that ensure your European business thrives. As a team of specialists, we stand for ophthalmology innovation in Europe.

Please visit: [www.medevisе.com](http://www.medevisе.com)





ophthalmology  
futures forums

Virtual2021

# SAVE THE DATE

## EUROPEAN VIRTUAL FORUMS

### European Forum *Virtual 2021*

Thurs. 07 October

*(Forums begin @ 12:30 Central European Summer Time)*

[www.ophthalmology-futures.com](http://www.ophthalmology-futures.com)



REGENXBIO®

SEEKING TO IMPROVE LIVES  
THROUGH THE CURATIVE  
POTENTIAL OF GENE THERAPY

## OUR COMMITMENT

REGENXBIO is committed to developing gene therapies that improve treatment options for people with serious diseases. The personal stories of patients and families help guide our work. We earn their trust through our actions and our words.

[REGENXBIO.com](http://REGENXBIO.com)

➤ For the latest updates on our programs, visit [REGENXBIO.com](http://REGENXBIO.com)

# PROGRAMME COMMITTEE

**Ike Ahmed** | Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

**Jorge Alio** | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visum Corporation, Spain.

**Gerd Auffarth** | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

**Francesco Bandello** | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

**David Chang** | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

**Steve Charles** | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

**Paul Chew** | Professor of Ophthalmology, National University of Singapore, Singapore.

**Beatrice Cochener** | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

**Jost Jonas** | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

**Sir Peng Khaw** | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

**Shigeru Kinoshita** | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

**Richard Lindstrom** | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

**Boris Malyugin** | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

**Prof David Spalton** | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

**Prof Dr Ingeborg Stalmans** | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

**Paulo Eduardo Stanga** | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

**Paul Rosen** | Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Oxford, UK.

**José-Alain Sahel** | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments

of Ophthalmology, Quinze- Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Julian D. Stevens** | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

**Donald Tan Tiang Hwee** | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

**Marie-Jose Tassignon** | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

**Adnan Tufail** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

**Tien Yin Wong** | Vice Dean, Academic & Clinical Development, Duke-NUS Medical School, Singapore. Provost's Chair Professor, National University of Singapore. Deputy Group CEO (Research & Education), SingHealth, Singapore. Medical Director & Senior Consultant Ophthalmologist, Singapore National Eye Centre. Chair, Ophthalmology & Visual Sciences Academic Clinical Programme. Chairman, Board of Directors, Singapore Eye Research Institute, Singapore.

## ADVISORS

**Laurent Attias** | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

**Eugene de Juan** | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

**Tom Dunlap** | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

**Malvina Eydelman** | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

**Akira Kurokawa** | Chairman. Santen Pharmaceutical Co.

**James Mazzo** | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

**Naveed Siddiqi** | Novo Ventures.

## ORGANISING COMMITTEE

**Keith Barton** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

**Don Budenz** | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

**Lea Pietrolongo** | Operational Director, Ophthalmology Futures Forums, UK.

**Kuldev Singh** | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Sanny Yuzhen Jiang** | Honorary Clinical Fellow. Moorfields Eye Hospital. Senior Research Associate, University College London Institute of Ophthalmology, UK.





# We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at [alcon.com](https://alcon.com)

## CONNECT WITH US!



@AlconEyeCare  
@AlconCareers



@Alcon



@AlconLife

